Collateral for a security interest recorded Apr 27, 2026 (Citibank, N.A.).
Term ends Apr 28, 2028 · Low confidence
20-year base term ends Apr 28, 2028
Held by BPCR Limited Partnership
Filed Jun 18, 2018 as application 16/011,068 · Granted Jan 7, 2020
Base term, 20 years from filing
Today
2008
2028
Clock starts
Apr 28, 2008
Apr 28, 2008
Term ends
Apr 28, 2028
Apr 28, 2028
Granted
Jan 7, 2020
Jan 7, 2020
base term
fee events
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 10,925,866, US 11,033,538, US 9,999,618, to Apr 28, 2028. The term already ends on or before that date, so the cap shortened nothing.
1 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
12
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 2 maintenance fees is paid so far. Confidence: Low. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Apr 28, 2008, when application PCT/US2008/061764, the earliest non-provisional in its chain, was filed (this one was filed Jun 18, 2018); a parent in its chain could not be resolved (the next row) | Apr 28, 2028 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,925,866, US 11,033,538, US 9,999,618) | resolves to Apr 28, 2028, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 2 maintenance fees paid | In force | High confidence |
| Further caveats on record | The record names parents not resolved: 15213920, 14713821 | Low confidence overall | Low confidence |
| Computed term end | The steps above, in order | Apr 28, 2028 | Low confidence |
This family
| US 9,056,101 | In force Nov 2030 | Nov 2030 |
| US 9,999,618 | In force Apr 2028 | Apr 2028 |
| US 10,925,866 | In force Apr 2028 | Apr 2028 |
| US 11,033,538 | In force Apr 2028 | Apr 2028 |
| US 10,525,045 | this patent Apr 2028 | Apr 2028 |
| US 12,070,453 | In force Jul 2036 | Jul 2036 |
| US 12,599,595 | In force Apr 2028 | Apr 2028 |
| US 12,599,594 | In force Jul 2036 | Jul 2036 |
8 of 12 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Sep 28, 2018 Reel 47004, frame 208 | Amicus Therapeutics, Inc. | Biopharma Credit PLC | Security Interest |
| May 11, 2020 Reel 52625, frame 916 | Amicus Therapeutics, Inc. | Biopharma Credit PLC | Security Interest |
| May 21, 2020 Reel 52741, frame 173 | Biopharma Credit PLC | BPCR Limited Partnership | Omnibus Confirmation of Assignment Agreement |
| Jul 30, 2020 Reel 53360, frame 659 | BPCR Limited Partnership | Amicus Therapeutics, Inc. | Release of Security Interest |
| Jul 30, 2020 Reel 53365, frame 342 | Amicus Therapeutics, Inc. | Hayfin Services LLP, as Agent | Security Interest |
| Oct 6, 2023 Reel 65177, frame 196 | Amicus Therapeutics, Inc. | Wilmington Trust, National Association | Security Interest |
| Oct 6, 2023 Reel 65164, frame 945 | Hayfin Services LLP | Amicus Therapeutics, Inc. | Release of Security Interest |
| Apr 27, 2026 Reel 75493, frame 968 | Biomarin Pharmaceutical Inc.; Amicus Therapeutics, Inc. | Citibank, N.A., as Collateral Agent | Security Interest |
| Apr 27, 2026 Reel 75494, frame 30 | Wilmington Trust, National Association | Amicus Therapeutics, Inc. | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Apr 2028
Term ends Apr 28, 2028. Maintenance fees still fall due before then
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 10,925,866, US 11,033,538, US 9,999,618, ends no earlier than this term, so it caps nothing.
Citations
48
later US patents cite this one
That is top 5% of utility patents granted in 2020 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.